These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 30038229)

  • 1. A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter.
    Amato D; Canneva F; Cumming P; Maschauer S; Groos D; Dahlmanns JK; Grömer TW; Chiofalo L; Dahlmanns M; Zheng F; Kornhuber J; Prante O; Alzheimer C; von Hörsten S; Müller CP
    Mol Psychiatry; 2020 Sep; 25(9):2101-2118. PubMed ID: 30038229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy of schizophrenia: Mechanisms of antipsychotic accumulation, therapeutic action and failure.
    Chestnykh DA; Amato D; Kornhuber J; Müller CP
    Behav Brain Res; 2021 Apr; 403():113144. PubMed ID: 33515642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time.
    Samaha AN; Seeman P; Stewart J; Rajabi H; Kapur S
    J Neurosci; 2007 Mar; 27(11):2979-86. PubMed ID: 17360921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the dopamine D2 receptor in schizophrenia.
    Seeman P
    Expert Opin Ther Targets; 2006 Aug; 10(4):515-31. PubMed ID: 16848689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
    Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
    Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
    Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
    Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability.
    Amato D; Vernon AC; Papaleo F
    Neurosci Biobehav Rev; 2018 Feb; 85():146-159. PubMed ID: 28970021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications.
    de Haan L; Lavalaye J; van Bruggen M; van Nimwegen L; Booij J; van Amelsvoort T; Linszen D
    Can J Psychiatry; 2004 May; 49(5):290-6. PubMed ID: 15198464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine D2 and D4 receptor ligands: relation to antipsychotic action.
    Wilson JM; Sanyal S; Van Tol HH
    Eur J Pharmacol; 1998 Jun; 351(3):273-86. PubMed ID: 9721018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs. [123I]epidepride single photon emission tomography (SPET) study.
    Bigliani V; Mulligan RS; Acton PD; Visvikis D; Ell PJ; Stephenson C; Kerwin RW; Pilowsky LS
    Br J Psychiatry; 1999 Sep; 175():231-8. PubMed ID: 10645324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data.
    Takeuchi H; Suzuki T; Bies RR; Remington G; Mamo DC; Pollock BG; Mimura M; Uchida H
    Schizophr Res; 2013 Nov; 150(2-3):373-9. PubMed ID: 24028745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis.
    Iyo M; Tadokoro S; Kanahara N; Hashimoto T; Niitsu T; Watanabe H; Hashimoto K
    J Clin Psychopharmacol; 2013 Jun; 33(3):398-404. PubMed ID: 23609386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [
    Slifstein M; Abi-Dargham A; Girgis RR; Suckow RF; Cooper TB; Divgi CR; Sokoloff P; Leriche L; Carberry P; Oya S; Joseph SK; Guiraud M; Montagne A; Brunner V; Gaudoux F; Tonner F
    Psychopharmacology (Berl); 2020 Feb; 237(2):519-527. PubMed ID: 31773210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications.
    Frankle WG; Gil R; Hackett E; Mawlawi O; Zea-Ponce Y; Zhu Z; Kochan LD; Cangiano C; Slifstein M; Gorman JM; Laruelle M; Abi-Dargham A
    Psychopharmacology (Berl); 2004 Oct; 175(4):473-80. PubMed ID: 15083259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of new antipsychotic medications: occupancy is not just antagonism.
    Grunder G; Carlsson A; Wong DF
    Arch Gen Psychiatry; 2003 Oct; 60(10):974-7. PubMed ID: 14557141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder--implications for psychopharmacology.
    Kasper S; Tauscher J; Willeit M; Stamenkovic M; Neumeister A; Küfferle B; Barnas C; Stastny J; Praschak-Rieder N; Pezawas L; de Zwaan M; Quiner S; Pirker W; Asenbaum S; Podreka I; Brücke T
    World J Biol Psychiatry; 2002 Jul; 3(3):133-46. PubMed ID: 12478878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
    Bernardo M; Parellada E; Lomeña F; Catafau AM; Font M; Gómez JC; López-Carrero C; Gutiérrez F; Pavía J; Salamero M
    Psychiatry Res; 2001 Aug; 107(2):87-97. PubMed ID: 11530275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
    Bigliani V; Mulligan RS; Acton PD; Ohlsen RI; Pike VW; Ell PJ; Gacinovic S; Kerwin RW; Pilowsky LS
    Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.